Skip to main content

VOLITIONRX LTD

For the period ended Mar 31, 2025. Filed May 15, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 15, 2025

VNRX$0.18-7.8%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Operations and Comprehensive Loss

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)

Three Months EndedMarch 31,
20252024
$$
Revenues
Service115,4762,938
Product130,909168,597
Total Revenues246,385171,535
Operating Expenses
Research and development2,607,4444,629,527
General and administrative2,243,3622,253,743
Sales and marketing917,2991,672,769
Total Operating Expenses5,768,1058,556,039
Operating Loss(5,521,720)(8,384,504)
Other Income (Expenses)
Grant income121,566-
Interest income1588,654
Interest expense(96,669)(77,233)
Gain (Loss) on change in fair value of warrant liability20,038(18,922)
Total Other Income (Expenses)45,093(87,501)
Net Loss(5,476,627)(8,472,005)
Net Loss attributable to Non-Controlling Interest52,868104,617
Net Loss attributable to VolitionRx Stockholders(5,423,759)(8,367,388)
Other Comprehensive Income (Loss)
Foreign currency translation adjustments(253,929)15,026
Net Comprehensive Loss(5,730,556)(8,456,979)
Loss Per Common Share – Attributable to Common Stockholders - Basic and Diluted(0.06)(0.10)
Weighted Average Shares Outstanding – Basic and Diluted96,536,05281,956,660
(The accompanying notes are an integral part of these condensed consolidated financial statements)
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.